: 958	10.4	86.7	94	14	AAQ48049	CMX5-1 light chain
: 959	10.4	86.7	94	18	AAT90309	Multiple cloning s
: 960	10.4	86.7	94	20	AAX51873	Human secreted pro
: 961	10.4	86.7	94	21	AAZ87725	Anti-human VEGF re
: 962	10.4	86.7	94	22	AAF86860	Ganglioside GD2 sp
: 963	10.4	86.7	94	22	AAF70202	Anti-human Flt-1 a
: 964	10.4	86.7	94	25	ABX17639	Modified rat DNA P
c 965	10.4	86.7	95	14	AAQ48068	Humanised antibody
966	10.4	86.7	95	18	AAT85862	CDR-grafted heavy
967	10.4	86.7	95	18	AAT65417	Transforming growt
c 968	10.4	86.7	95	22	AAF86876	Ganglioside GD3 sp
c 969	10.4	86.7	95	25	ABX17344	Modified gangliosi
c 970	10.4	86.7	95	25	ABX17660	Modified rat DNA P
971	10.4	86.7	96	14	AAQ38886	gH1 variable domai
c 972	10.4	86.7	96	21	AAZ87732	Anti-human VEGF re
973	10.4	86.7	96	21	AAZ87737	Anti-human VEGF re
974	10.4	86.7	96	21	AAZ46921	gH1 variable domai
975	10.4	86.7	96	22	AAF86865	Ganglioside GD2 sp
c 976	10.4	86.7	96	22	AAF70209	Anti-human Flt-1 a
977	10.4	86.7	96	22	AAF70214	Anti-human Flt-1 a
978	10.4	86.7	96	25	AAL51521	Human Nkd (hNkd) g
c 979	10.4	86.7	97	14	AAQ48072	Humanised antibody
c 980	10.4	86.7	97	15	AAQ44725	Oligonucleotide us
c 981	10.4	86.7	97	18	AAT73618	Primer used in pre
c 982	10.4	86.7	97	20	AAZ28559	Oligonucleotide C2
c 983	10.4	86.7	97	22	ABA74310	Human foetal liver
c 984	10.4	86.7	97	22	AAK22776	Human brain expres
c 985	10.4	86.7	97	22	AAK48945	Human bone marrow
c 986	10.4	86.7	97	22	AAI54773	Probe #23459 used
c 987	10.4	86.7	97	23	ABS48611	Human liver single
c 988	10.4	86.7	97	25	ABX17664	Modified rat DNA P
c 989	10.4	86.7	98	21	AAC60331	Primer PVp1. Synt
990	10.4	86.7	98	21	AAC60332	Primer Pvp2. Synt
c 991	10.4	86.7	98	22	AAF75455	Codon-optimised HP
992	10.4	86.7	100	16	AAT20394	Human gene signatu
993	10.4	86.7	100	18	AAT73623	Primer used in pre
c 994	10.4	86.7	100	19	AAV08056	Fragment of gangli
c 995	10.4	86.7	100	20	AAZ06265	Primer Z06265 for
996	10.4	86.7	100	21	AAZ51661	Human PRG1 derived
997	10	83.3	12	23	ABI78373	Oligonucleotide pr
998	10	83.3	12	23	ABI78374	Oligonucleotide pr
c 999	10	83.3	13	14	AAQ52487	pING4533 Kozak seq
c1000	10	83.3	13	15	AAQ67275	Consensus Kozak tr

ALIGNMENTS

RESULT 1
AAQ77634
ID AAQ77634 standard; RNA; 18 BP.
XX
AC AAQ77634;
XX
DT 25-MAR-2003 (updated)
DT 02-JUN-1995 (first entry)
XX
DE Ribonucleotide to tenascin gene consensus mRNA initiation site -9-+9.
XX
KW Antisense; polynucleotide; sense strand; tenascin; complementary;
KW consensus; initiation; extracellular; glycoprotein; muscle; translation;
KW proliferation; growth stimulatory; transcription; vascular stenosis;
KW post-angioplasty; restenosis; cardiac hypertrophy; vascular surgery;
KW organ transplant; ds.
XX
OS Synthetic.
XX
PN WO9421664-A1.
XX
PD 29-SEP-1994.
XX
PF 24-MAR-1994; 94WO-US03206.
XX
PR 25-MAR-1993; 93US-0037025.
XX
PA (TEXA-) TEXAS BIOTECHNOLOGY CORP.
XX
PI Denner LA, Dixon RAF, Rege AA, Stacy DL;
XX
DR WPI; 1994-316926/39.
XX
PT Synthetic anti-sense polynucleotide - hybridises to tenascin
PT gene, useful for inhibiting vascular smooth muscle cell
PT proliferation.
XX
PS Claim 5; Page 47; 64pp; English.
XX
CC A series of polynucleotides, either DNA (AAQ76388 and AAQ76392-400 and
CC AAQ77614-18) or RNA (AAQ76390 and AAQ77633-46), directed against the
CC consensus mRNA initiation site sequence (AAQ77661) for the tenascin gene.
CC The polynucleotides are based on the degenerate sequence (AAQ76386) of
CC the tenascin gene. Tenascin is an extracellular matrix glycoprotein
CC consisting six disulphide-linked subunits, each having molecular mass of
CC 190-250 kDa. Tenascin may be important for smooth muscle cell
CC proliferation as the protein has growth stimulatory activity. The
CC polynucleotides can be used to inhibit transcription of the gene or
CC translation of the mRNA encoding tenascin. The method is applicable to a
CC number of diseases where the proliferation of smooth muscle is involved
CC e.g. vascular stenosis, post-angioplasty restenosis and other
CC non-angioplasty procedures such as cardiac hypertrophy, vascular surgery
CC and organ transplant.
CC (Updated on 25-MAR-2003 to correct PN field.)
XX
SQ Sequence 18 BP; 2 A; 5 C; 8 G; 3 U; 0 other;

Query Match 100.0%; Score 12; DB 15; Length 18;
Best Local Similarity 83.3%; Pred. No. 2.8e+03;
Matches 10; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 CCATGGTGGAGG 12
              |||:||:|||||
Db          6 CCAUGGUGGAGG 17
```

RESULT 2
AAQ77620/c
ID AAQ77620 standard; DNA; 18 BP.
XX
AC AAQ77620;
XX
DT 25-MAR-2003 (updated)
DT 01-JUN-1995 (first entry)
XX
DE Antisense polynucleotide binds to tenascin gene consensus at -9-+9.
XX
KW Antisense; polynucleotide; sense strand; tenascin; complementary;
KW consensus; initiation; extracellular; glycoprotein; muscle; translation;
KW proliferation; growth stimulatory; transcription; vascular stenosis;
KW post-angioplasty; restenosis; cardiac hypertrophy; vascular surgery;
KW organ transplant; ds.
XX
OS Synthetic.
XX
FH Key Location/Qualifiers

```
XX
PD   29-SEP-1994.
XX
PF   24-MAR-1994;   94WO-US03206.
XX
PR   25-MAR-1993;   93US-0037025.
XX
PA   (TEXA-) TEXAS BIOTECHNOLOGY CORP.
XX
PI   Denner LA,  Dixon RAF,  Rege AA,  Stacy DL;
XX
DR   WPI; 1994-316926/39.
XX
PT   Synthetic anti-sense polynucleotide - hybridises to tenascin
PT   gene, useful for inhibiting vascular smooth muscle cell
PT   proliferation.
XX
PS   Claim 10; Page 44; 64pp; English.
XX
CC   A series of antisense polynucleotides, either DNA (AAQ76388 and
CC   AAQ77619-32) or RNA (AAQ76390 and AAQ77647-60) directed against the sense
CC   strand of the gene encoding tenascin.  The polynucleotides are based on
CC   the complementary sequence (AAQ76386) of the consensus mRNA initiation
CC   site sequence (AAQ77661) for the tenascin gene.  Tenascin is an
CC   extracellular matrix glycoprotein consisting six disulphide-linked
CC   subunits, each having molecular mass of 190-250 kDa.  Tenascin may be
CC   important for smooth muscle cell proliferation as the protein has growth
CC   stimulatory activity.  The polynucleotides can be used to inhibit
CC   transcription of the gene or translation of the mRNA encoding tenascin.
CC   The method is applicable to a number of diseases where the proliferation
CC   of smooth muscle is involved e.g. vascular stenosis, post-angioplasty
CC   restenosis and other non-angioplasty procedures such as cardiac
CC   hypertrophy, vascular surgery and organ transplant.
CC   (Updated on 25-MAR-2003 to correct PN field.)
XX
SQ   Sequence 18 BP; 3 A; 8 C; 5 G; 2 T; 0 other;

  Query Match             100.0%;  Score 14;  DB 15;  Length 18;
  Best Local Similarity   100.0%;  Pred. No. 4.8e+02;
  Matches   14;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 CCCCATGGTGGAGG 14
              ||||||||||||||
Db         15 CCCCATGGTGGAGG 2


RESULT 3
AAQ77648/c
ID   AAQ77648 standard; RNA; 18 BP.
XX
AC   AAQ77648;
XX
DT   25-MAR-2003  (updated)
DT   02-JUN-1995  (first entry)
XX
DE   Antisense ribonucleotide binds to tenascin gene consensus at -9-+9.
XX
KW   Antisense; polynucleotide; sense strand; tenascin; complementary;
KW   consensus; initiation; extracellular; glycoprotein; muscle; translation;
KW   proliferation; growth stimulatory; transcription; vascular stenosis;
KW   post-angioplasty; restenosis; cardiac hypertrophy; vascular surgery;
KW   organ transplant; ds.
XX
OS   Synthetic.
XX
FH   Key             Location/Qualifiers
FT   misc_difference 1..18
FT                   /*tag=  a
FT                   /note= "phosphodiester bonds between nucleotides
FT                           may be replaced by phosphorothioate bonds"
XX
PN   WO9421664-A1.
XX
PD   29-SEP-1994.
XX
PF   24-MAR-1994;   94WO-US03206.
XX
PR   25-MAR-1993;   93US-0037025.
XX
PA   (TEXA-) TEXAS BIOTECHNOLOGY CORP.
XX
PI   Denner LA,  Dixon RAF,  Rege AA,  Stacy DL;
XX
DR   WPI; 1994-316926/39.
XX
PT   Synthetic anti-sense polynucleotide - hybridises to tenascin
PT   gene, useful for inhibiting vascular smooth muscle cell
PT   proliferation.
XX
PS   Claim 10; Page 51; 64pp; English.
XX
CC   A series of antisense polynucleotides, either DNA (AAQ76388 and
CC   AAQ77619-32) or RNA (AAQ76390 and AAQ77647-60) directed against the sense
CC   strand of the gene encoding tenascin.  The polynucleotides are based on
CC   the complementary sequence (AAQ76386) of the consensus mRNA initiation
CC   site sequence (AAQ77661) for the tenascin gene.  Tenascin is an
CC   extracellular matrix glycoprotein consisting six disulphide-linked
CC   subunits, each having molecular mass of 190-250 kDa.  Tenascin may be
CC   important for smooth muscle cell proliferation as the protein has growth
CC   stimulatory activity.  The polynucleotides can be used to inhibit
CC   transcription of the gene or translation of the mRNA encoding tenascin.
CC   The method is applicable to a number of diseases where the proliferation
CC   of smooth muscle is involved e.g. vascular stenosis, post-angioplasty
CC   restenosis and other non-angioplasty procedures such as cardiac
CC   hypertrophy, vascular surgery and organ transplant.
CC   (Updated on 25-MAR-2003 to correct PN field.)
XX
SQ   Sequence 18 BP; 3 A; 8 C; 5 G; 2 U; 0 other;

  Query Match             100.0%;  Score 14;  DB 15;  Length 18;
  Best Local Similarity   100.0%;  Pred. No. 4.8e+02;
  Matches   14;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 CCCCATGGTGGAGG 14
              ||||||||||||||
Db         15 CCCCATGGTGGAGG 2


RESULT 4
AAQ76393
ID   AAQ76393 standard; DNA; 18 BP.
XX
AC   AAQ76393;
XX
DT   25-MAR-2003  (updated)
DT   02-JUN-1995  (first entry)
XX
DE   Polynucleotide to tenascin gene consensus mRNA initiation site -9-+9.
XX
KW   Antisense; polynucleotide; sense strand; tenascin; complementary;
KW   consensus; initiation; extracellular; glycoprotein; muscle; translation;
KW   proliferation; growth stimulatory; transcription; vascular stenosis;
KW   post-angioplasty; restenosis; cardiac hypertrophy; vascular surgery;
KW   organ transplant; ds.
XX
OS   Synthetic.
XX
FH   Key             Location/Qualifiers
FT   misc_difference 1..18
FT                   /*tag=  a
FT                   /note= "phosphodiester bonds between nucleotides
FT                           may be replaced by phosphorothioate bonds"
XX
PN   WO9421664-A1.
XX
PD   29-SEP-1994.
```

c 958	10.4	74.3	89	22	AAK44523	Human bone marrow
c 959	10.4	74.3	89	22	AAI50512	Probe #19198 used
c 960	10.4	74.3	89	23	ABS44181	Human liver single
c 961	10.4	74.3	89	24	ABS18760	Human genome-deriv
962	10.4	74.3	90	20	AAH87016	Human single nucle
963	10.4	74.3	90	24	ABK36944	Human DNA encoding
964	10.4	74.3	91	24	ABL74647	Corn tassel-derive
965	10.4	74.3	92	24	AAD28212	Plasmid pTimer-1 D
966	10.4	74.3	94	21	AAA07989	Vector pEGFP-N1 DN
967	10.4	74.3	94	22	AAC81526	Plasmid pEGFP-N1 f
968	10.4	74.3	94	25	AAL54302	DNA region of plas
969	10.4	74.3	95	24	ABV95815	Human pancreatic c
c 970	10.4	74.3	99	21	AAA98099	A. aeolicus lumazi
971	10.2	72.9	20	21	AAC63973	Icelandic scallop
972	10	71.4	10	21	AAC60401	Example translatio
973	10	71.4	10	21	AAA39090	Control sequence o
974	10	71.4	10	22	AAD06402	Translation initia
975	10	71.4	10	22	AAH19564	Translation initia
976	10	71.4	10	24	ABK95227	Translation initia
977	10	71.4	10	24	AAS16881	Translation initia
978	10	71.4	14	20	AAV92785	Human A-raf target
c 979	10	71.4	15	24	AAS19541	ASO primer #10 to
980	10	71.4	17	25	ABZ62149	Human H-Ras DNAzym
c 981	10	71.4	18	24	ABN89448	Human Ztnfr12-Fc5
c 982	10	71.4	19	21	AAA98699	Nucleic acid combi
c 983	10	71.4	19	25	ABT31711	G protein coupled
c 984	10	71.4	20	17	AAT16966	Human/murine chima
c 985	10	71.4	20	19	AAV29783	PCR primer for bov
c 986	10	71.4	20	19	AAV22545	Antisense oligonuc
c 987	10	71.4	20	21	AAC58843	B. anthracis micro
c 988	10	71.4	20	21	AAA90774	Ribonucleotide red
989	10	71.4	20	24	ABI95220	Capture oligonucle
c 990	10	71.4	20	25	ABT32097	NOVX probe SEQ ID
c 991	10	71.4	20	25	ABT31701	G protein coupled
992	10	71.4	21	16	AAQ79657	Primer OTG5015 to
993	10	71.4	21	21	AAA14614	Sense PCR primer u
c 994	10	71.4	21	24	ABZ31021	Candida albicans G
995	10	71.4	21	24	ABS51275	Human CADPKL DNA s
c 996	10	71.4	23	15	AAQ58892	Alpha globin promo
c 997	10	71.4	23	19	AAV17030	GAPDH PCR primer K
c 998	10	71.4	23	19	AAV16993	GAPDH house-keepin
c 999	10	71.4	23	22	AAH78157	Nucleotide sequenc
c1000	10	71.4	23	24	ABX00130	Mouse MABL-2 scFv

ALIGNMENTS

RESULT 1
AAQ77634
ID AAQ77634 standard; RNA; 18 BP.
XX
AC AAQ77634;
XX
DT 25-MAR-2003 (updated)
DT 02-JUN-1995 (first entry)
XX
DE Ribonucleotide to tenascin gene consensus mRNA initiation site -9-+9.
XX
KW Antisense; polynucleotide; sense strand; tenascin; complementary;
KW consensus; initiation; extracellular; glycoprotein; muscle; translation;
KW proliferation; growth stimulatory; transcription; vascular stenosis;
KW post-angioplasty; restenosis; cardiac hypertrophy; vascular surgery;
KW organ transplant; ds.
XX
OS Synthetic.
XX
FH Key Location/Qualifiers
FT misc_difference 1..18
FT /*tag= a
FT /note= "phosphodiester bonds between nucleotides
FT may be replaced by phosphorothioate bonds"
XX
PN WO9421664-A1.
XX
PD 29-SEP-1994.
XX
PF 24-MAR-1994; **94WO-US03206**.
XX
PR 25-MAR-1993; 93US-0037025.
XX
PA (TEXA-) TEXAS BIOTECHNOLOGY CORP.
XX
PI Denner LA, Dixon RAF, Rege AA, Stacy DL;
XX
DR WPI; 1994-316926/39.
XX
PT Synthetic anti-sense polynucleotide - hybridises to tenascin
PT gene, useful for inhibiting vascular smooth muscle cell
PT proliferation.
XX
PS Claim 5; Page 47; 64pp; English.
XX
CC A series of polynucleotides, either DNA (AAQ76388 and AAQ76392-400 and
CC AAQ77614-18) or RNA (AAQ76390 and AAQ77633-46), directed against the
CC consensus mRNA initiation site sequence (AAQ77661) for the tenascin gene.
CC The polynucleotides are based on the degenerate sequence (AAQ76386) of
CC the tenascin gene. Tenascin is an extracellular matrix glycoprotein
CC consisting six disulphide-linked subunits, each having molecular mass of
CC 190-250 kDa. Tenascin may be important for smooth muscle cell
CC proliferation as the protein has growth stimulatory activity. The
CC polynucleotides can be used to inhibit transcription of the gene or
CC translation of the mRNA encoding tenascin. The method is applicable to a
CC number of diseases where the proliferation of smooth muscle is involved
CC e.g. vascular stenosis, post-angioplasty restenosis and other
CC non-angioplasty procedures such as cardiac hypertrophy, vascular surgery
CC and organ transplant.
CC (Updated on 25-MAR-2003 to correct PN field.)
XX
SQ Sequence 18 BP; 2 A; 5 C; 8 G; 3 U; 0 other;

Query Match 100.0%; Score 14; DB 15; Length 18;
Best Local Similarity 85.7%; Pred. No. 3.9e+02;
Matches 12; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 GGCCCCCATGGTGG 14
              ||||||||:||:||
Db          1 GGCCCCCAUGGUGG 14
```

RESULT 2
AAQ77620/c
ID AAQ77620 standard; DNA; 18 BP.
XX
AC AAQ77620;
XX
DT 25-MAR-2003 (updated)
DT 01-JUN-1995 (first entry)
XX
DE Antisense polynucleotide binds to tenascin gene consensus at -9-+9.
XX
KW Antisense; polynucleotide; sense strand; tenascin; complementary;
KW consensus; initiation; extracellular; glycoprotein; muscle; translation;
KW proliferation; growth stimulatory; transcription; vascular stenosis;
KW post-angioplasty; restenosis; cardiac hypertrophy; vascular surgery;
KW organ transplant; ds.
XX
OS Synthetic.
XX
FH Key Location/Qualifiers
FT misc_difference 1..18
FT /*tag= a
FT /note= "phosphodiester bonds between nucleotides
FT may be replaced by phosphorothioate bonds"
XX
PN WO9421664-A1.

c 958	11.2	65.9	53	13	AAQ29702	IRS-1 probe 80. S
959	11.2	65.9	53	24	AAD28809	Primer, T7VH used
960	11.2	65.9	53	24	ABL31941	PCR amplified DNA
961	11.2	65.9	53	24	ABL31966	FokI/FspI containi
c 962	11.2	65.9	54	17	AAT42503	Primer for preproH
c 963	11.2	65.9	54	19	AAV41808	Human pancreatic c
c 964	11.2	65.9	54	22	AAH23431	Empedobacter brevi
965	11.2	65.9	54	24	ABL31975	PCR amplified DNA
966	11.2	65.9	55	24	ABL31919	Target DNA oligonu
c 967	11.2	65.9	57	16	AAT25716	Human gene signatu
c 968	11.2	65.9	57	16	AAT24085	Human gene signatu
c 969	11.2	65.9	57	22	AAL02932	Human reproductive
c 970	11.2	65.9	58	16	AAT23484	Human gene signatu
971	11.2	65.9	59	14	AAQ48344	MAb 25D2 light cha
972	11.2	65.9	59	14	AAQ47032	HCV NS3/NS4 sequen
973	11.2	65.9	59	19	AAV30024	PCR primer used to
974	11.2	65.9	59	22	AAD21205	Sense PCR primer #
975	11.2	65.9	59	25	ABX96900	Hepatitis C virus
976	11.2	65.9	59	25	ABX80039	Hepatitis C virus
977	11.2	65.9	60	24	ABX96650	Human p53 gene oli
978	11.2	65.9	60	24	ABX96651	Human p53 gene oli
c 979	11.2	65.9	60	24	ABQ96109	Tumour suppression
980	11.2	65.9	60	24	ABN86436	Kozak consensus mo
981	11.2	65.9	60	24	ABN32585	Human spliced tran
c 982	11.2	65.9	60	24	ABN32925	Human spliced tran
c 983	11.2	65.9	60	24	ABN36580	Human spliced tran
c 984	11.2	65.9	60	24	ABN36976	Human spliced tran
985	11.2	65.9	60	24	ABN37924	Human spliced tran
c 986	11.2	65.9	60	24	ABN39985	Human spliced tran
c 987	11.2	65.9	60	24	ABN40204	Human spliced tran
988	11.2	65.9	60	24	ABN40863	Human spliced tran
989	11.2	65.9	60	24	ABN43625	Human spliced tran
990	11.2	65.9	60	24	ABN49041	Human spliced tran
991	11.2	65.9	60	24	ABN59120	Human spliced tran
c 992	11.2	65.9	60	24	AAD30991	Bridging oligo #1
993	11.2	65.9	62	24	AAD30980	Bridging oligo #1
c 994	11.2	65.9	63	21	AAZ32763	Chimeric antibody
c 995	11.2	65.9	63	25	ABT21668	Breast cancer mark
996	11.2	65.9	64	16	AAT22590	Human gene signatu
997	11.2	65.9	65	24	ABN28152	Rat spliced transc
998	11.2	65.9	65	24	ABN30112	Rat spliced transc
999	11.2	65.9	65	24	ABN54076	Mouse spliced tran
c1000	11.2	65.9	65	24	ABN58260	Mouse spliced tran

ALIGNMENTS

```
RESULT 1
AAQ77634
ID   AAQ77634 standard; RNA; 18 BP.
XX
AC   AAQ77634;
XX
DT   25-MAR-2003  (updated)
DT   02-JUN-1995  (first entry)
XX
DE   Ribonucleotide to tenascin gene consensus mRNA initiation site -9-+9.
XX
KW   Antisense; polynucleotide; sense strand; tenascin; complementary;
KW   consensus; initiation; extracellular; glycoprotein; muscle; translation;
KW   proliferation; growth stimulatory; transcription; vascular stenosis;
KW   post-angioplasty; restenosis; cardiac hypertrophy; vascular surgery;
KW   organ transplant; ds.
XX
OS   Synthetic.
XX
FH   Key             Location/Qualifiers
FT   misc_difference 1..18
FT                   /*tag=  a
FT                   /note= "phosphodiester bonds between nucleotides
                     may be replaced by phosphorothioate bonds"
PN   WO9421664-A1.
XX
PD   29-SEP-1994.
XX
PF   24-MAR-1994;   94WO-US03206.
XX
PR   25-MAR-1993;   93US-0037025.
XX
PA   (TEXA-) TEXAS BIOTECHNOLOGY CORP.
XX
PI   Denner LA,  Dixon RAF,  Rege AA,  Stacy DL;
XX
DR   WPI; 1994-316926/39.
XX
PT   Synthetic anti-sense polynucleotide - hybridises to tenascin
PT   gene, useful for inhibiting vascular smooth muscle cell
PT   proliferation.
XX
PS   Claim 5; Page 47; 64pp; English.
XX
CC   A series of polynucleotides, either DNA (AAQ76388 and AAQ76392-400 and
CC   AAQ77614-18) or RNA (AAQ76390 and AAQ77633-46), directed against the
CC   consensus mRNA initiation site sequence (AAQ77661) for the tenascin gene.
CC    The polynucleotides are based on the degenerate sequence (AAQ76386) of
CC   the tenascin gene.  Tenascin is an extracellular matrix glycoprotein
CC   consisting six disulphide-linked subunits, each having molecular mass of
CC   190-250 kDa.  Tenascin may be important for smooth muscle cell
CC   proliferation as the protein has growth stimulatory activity.  The
CC   polynucleotides can be used to inhibit transcription of the gene or
CC   translation of the mRNA encoding tenascin. The method is applicable to a
CC   number of diseases where the proliferation of smooth muscle is involved
CC   e.g. vascular stenosis, post-angioplasty restenosis and other
CC   non-angioplasty procedures such as cardiac hypertrophy, vascular surgery
CC   and organ transplant.
CC   (Updated on 25-MAR-2003 to correct PN field.)
XX
SQ   Sequence 18 BP; 2 A; 5 C; 8 G; 3 U; 0 other;

  Query Match             100.0%;  Score 17;  DB 15;  Length 18;
  Best Local Similarity   88.2%;  Pred. No. 56;
  Matches   15;  Conservative    2;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 GGCCCCCATGGTGGAGG 17
              |||||||:||:|||||
Db          1 GGCCCCCAUGGUGGAGG 17


RESULT 2
AAQ77620/c
ID   AAQ77620 standard; DNA; 18 BP.
XX
AC   AAQ77620;
XX
DT   25-MAR-2003  (updated)
DT   01-JUN-1995  (first entry)
XX
DE   Antisense polynucleotide binds to tenascin gene consensus at -9-+9.
XX
KW   Antisense; polynucleotide; sense strand; tenascin; complementary;
KW   consensus; initiation; extracellular; glycoprotein; muscle; translation;
KW   proliferation; growth stimulatory; transcription; vascular stenosis;
KW   post-angioplasty; restenosis; cardiac hypertrophy; vascular surgery;
KW   organ transplant; ds.
XX
OS   Synthetic.
XX
FH   Key             Location/Qualifiers
FT   misc_difference 1..18
FT                   /*tag=  a
FT                   /note= "phosphodiester bonds between nucleotides
FT                    may be replaced by phosphorothioate bonds"
XX
PN   WO9421664-A1.
```